Jobs
-
Spexis (formerly Polyphor) said that a Phase 1 study of inhaled murepavadin, which the company is developing for the treatment of P. aeruginosa lung infections, demonstrated that the inhaled formulation delivered via the PARI eFlow nebulizer was well… Read more . . .
-
Liquidia Corporation said that an investment by HealthCare Royalty (HCRx) of up to $100 million will support further clinical development and the potential launch of the company’s Yutrepia treprostinil DPI. In return, HCRx will get tiered royalties… Read more . . .
-
TFF Pharmaceuticals, which is developing dry powder inhaled and nasal formulations based on its thin film freezing particle engineering technology, has announced the appointment of Zamaneh Mikhak as Chief Medical Officer. Mikhak was most recently… Read more . . .
-
The US Department of Defense Chemical and Biological Defense Program (CBDP) has awarded Australian pharma company ENA Respiratory $4.38 million for development of a dry powder formulation of the company’s INNA-051 intranasal pegylated TLR2/6 agonist for… Read more . . .
-
Lupin announced that it has launched its Difizma indacaterol / glycopyrronium / mometasone DPI in India for the treatment of inadequately controlled asthma. The company says that Difizma is the first fixed dose combination approved… Read more . . .
-
Acorda Therapeutics announced that it has signed a new supply agreement with Catalent that reduces the amount of product that the company is required to buy annually from $18 million to $8.5 million for 2023… Read more . . .
-
BiondVax Pharmaceuticals announced that 6 days post infection, hamsters treated with the company’s NanoAb inhaled nanosized antibodies had levels of SARS-COV-2 in their lungs reduced to levels 30 times lower than hamsters that got an… Read more . . .
-
Inhaled antiviral developer Pneumagen has announced the appointment of Adaptimmune Therapeutics founder James Noble as non-executive Chairman of the company’s board of directors. Noble also co-founded Immunocore and serves as Chairman of Sutura Therapeutics, Celleron,… Read more . . .
-
Pulmatrix has announced that a Phase 1 PK trial of its PUR3100 dihydroergotamine (DHE) DPI in healthy volunteers demonstrated that all 3 doses tested produced peak exposures in the desired range with a Tmax of… Read more . . .
-
Copley Scientific has announced the appointments of Jamie Clayton as Managing Director and Matthew Fenn as Head of Business Development. Clayton joined powder characterization specialist Freeman Technology in 2008 and then served as Freeman’s Operations… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA